This Supplementary Prospectus is dated 28 October 2021 (Supplementary Prospectus) and is intended to supplement and amend the information contained in the Prospectus dated 14 October 2021 (Prospectus) issued by Radiopharm Theranostics Limited ACN 647 877 889 (Company or Radiopharm) to raise $50 million through the issue of 83,333,333 fully paid ordinary shares in the Company.
This Supplementary Prospectus was lodged with the Australian Securities and Investments Commission (ASIC) and the Australian Securities Exchange (ASX) on 28 October 2021. Neither ASIC nor the ASX take responsibility for the contents of this Supplementary Prospectus.
For more information, download the attached PDF.
Download this document
